The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.
May 4th 2024
18F-DCFPyL PSMA-PET imaging plus multi-parametric MRI improved the detection of clinically significant prostate cancer in low- and high-risk men on active surveillance.
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
2023 ASCO Direct™ Highlights: Practice-Changing Data From the Leading Oncology Conference
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Dr. McKay Discusses Dutasteride in Prostate Cancer
February 20th 2014Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, Boston, Massachusetts, explains the mechanism of action of dutasteride and its role in a phase II trial in which abiraterone acetate was combined with dutasteride in men with metastatic castration-resistant prostate cancer
Adding Chemotherapy to ADT Improves Survival in Metastatic Prostate Cancer
February 5th 2014Administering chemotherapy concurrently with androgen deprivation therapy (ADT), rather than saving cytotoxic treatment until after progression, improves overall survival for men with hormone-sensitive metastatic prostate cancer
Dr. Beer on the Implications of the PREVAIL Study
February 3rd 2014Tomasz Beer, MD, FACP, professor of Medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, discusses the treatment of metastatic castration-resistant prostate cancer (mCRPC) with abiraterone and enzalutamide as it relates to results from the PREVAIL study.
Three Studies Provide Insights About Combining/Sequencing Abiraterone
Patients with metastatic castration-resistant prostate cancer (mCRPC) who have detectable serum androgen levels despite treatment with ketoconazole experience prostate-specific antigen (PSA) response to subsequent abiraterone acetate
Follow-up Confirms Safety of Radium-223 in mCRPC
Extended follow-up of patients with castration-resistant prostate cancer (CRPC) and bone metastases randomized to radium-223 dichloride (Xofigo) in the phase III ALSYMPCA study revealed a continued low incidence of myelosuppression and no association with secondary malignancies.
Dr. Tagawa on Abiraterone Plus Docetaxel in mCRPC
January 30th 2014Scott T. Tagawa, MD, assistant professor of medicine, medical director, Genitourinary Oncology Research Program, Weill Cornell Medical College, discusses the results of a study that evaluated the safety of abiraterone acetate combined with docetaxel in patients with metastatic castration-resistant prostate cancer that were presented at the 2014 Genitourinary Cancer Symposium in San Francisco.
Pre-Chemo Enzalutamide OS Benefit in mCRPC Reaches Nearly 30%
January 28th 2014The androgen-receptor blocker enzalutamide (Xtandi) improves survival by nearly 30% in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC) and delays progression of their disease by more than 80%
Overuse of Bone Scans Demonstrated in Low- and Intermediate-Risk Patients with Prostate Cancer
January 17th 2014Researchers in the Department of Radiation Oncology at the University of North Carolina Hospitals found that almost one-third of low-risk and almost one-half of intermediate-risk prostate cancer patients received a staging bone scan.
Study: Degarelix Before Leuprolide Can Eliminate Testosterone Surge
December 31st 2013Patients who undergo androgen deprivation therapy (ADT) to manage advanced prostate cancer will often face the prospect of a potentially dangerous testosterone surge before the downregulation of leuteinizing hormone (LH) secretion occurs and, within about 3 weeks, testosterone drops to castration-like levels.
Hot Flash Treatments That Help Women Fail to Benefit Androgen-Deprived Men
December 20th 2013Men who experience hot flashes because they are undergoing androgen-deprivation therapy for prostate cancer are not significantly helped by two treatments that alleviate that symptom in menopausal women, the results of a study show.